Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
December 11, 2017
Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
NEWTON, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
December 11, 2017
Achaogen Appoints Blake Wise Chief Executive Officer
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...
December 11, 2017
Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
LAVAL, QC, Dec. 11, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) announced today that its orally-active drug candidate, PBI-4050, has been issued a Promising Innovative ...
December 11, 2017
ADMA Files Biologics License Application For Its Third Plasma Collection Center
RAMSEY, N.J. and MARIETTA, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company ...
December 11, 2017
Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma
IRVING, Texas, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the presentation of interim ...
December 11, 2017
Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
December 11, 2017
Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial
GAITHERSBURG, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) --  Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug ...
December 11, 2017
Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis
NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (FBIO) Company focused on developing treatments for rare and ...
December 11, 2017
German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial
MONMOUTH JUNCTION, N.J., Dec. 11, 2017 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around ...
December 11, 2017
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
December 11, 2017
Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium
ROCKVILLE, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
December 8, 2017
OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
NANTES, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today announces that the Independent Data Monitoring Committee (IDMC) has recommended to the ...
December 8, 2017
iCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer Treatment
NASHUA, N.H., Dec. 07, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the ...
December 8, 2017
Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate ...
December 8, 2017
Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Copenhagen, December 7, 2017 - Zealand Pharma A/S ("Zealand") announces the initiation of the second Phase 3 trial to confirm the clinical efficacy and safety ...
December 8, 2017
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
AUSTIN, Texas, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme ...
December 8, 2017
Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology
REDWOOD CITY, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
December 6, 2017
Kiadis Pharma to lease existing commercial manufacturing facility in The Netherlands
AMSTERDAM & DUIVENDRECHT, Netherlands--(BUSINESS WIRE)-- Regulatory News: Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell ...
December 6, 2017
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
LIESTAL, Switzerland, OXFORD, England and CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Santhera Pharmaceuticals (SIX:SANN), Summit Therapeutics (SMMT) (SUMM.L), Catabasis Pharmaceuticals (CATB) and Duchenne ...
December 6, 2017
Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology
LAVAL, QC, Dec. 6, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that it will have two presentations at the 59th American ...
Page 73 of 117